Source:http://linkedlifedata.com/resource/pubmed/id/16804904
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2006-8-30
|
pubmed:abstractText |
We investigated the expression and prognostic significance of matrix metalloproteinase (MMP) -7, its relation to beta-catenin expression and clinicopathological factors in epithelial ovarian cancer. The expression of MMP-7 was analyzed immunohistochemically in a series of 284 primary epithelial ovarian cancers, their 36 metastases and 8 normal ovaries. In cancers with endometrioid histology, a high percentage area of MMP-7 expression and an intense MMP-7 signal was significantly associated with nuclear positivity of beta-catenin in cancer cells (p = 0.003, chi2 = 8.853 and p = 0.030, chi2 = 4.713, respectively). In all tumors and nonendometrioid subgroup, a low percentage area of MMP-7 positive tumor cells was significantly correlated with a high histological grade of the tumor (p = 0.003 and 0.005, respectively), in all tumors also with advanced stage of the tumor (p = 0.002) and large primary residual tumor (p = 0.005). A 10-year disease-related survival (DRS) was significantly better when the percentage area of MMP-7 expression in cancer cells was high, when compared to low (p = 0.0008). A high percentage area of intense MMP-7 signal in cancer cells predicted a significantly more favorable DRS and recurrence-free survival (RFS) (p = 0.0003 and 0.0052, respectively). In multivariate analysis, a high percentage area of intense MMP-7 signal in tumor cells was an independent prognostic factor, predicting favorable DRS and RFS. The present study showed that intense MMP-7 signal in tumor cells is an independent prognostic factor predicting better survival in epithelial ovarian cancer.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2006 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
119
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1792-9
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:16804904-Adolescent,
pubmed-meshheading:16804904-Adult,
pubmed-meshheading:16804904-Aged,
pubmed-meshheading:16804904-Aged, 80 and over,
pubmed-meshheading:16804904-Epithelial Cells,
pubmed-meshheading:16804904-Female,
pubmed-meshheading:16804904-Follow-Up Studies,
pubmed-meshheading:16804904-Humans,
pubmed-meshheading:16804904-Matrix Metalloproteinase 7,
pubmed-meshheading:16804904-Middle Aged,
pubmed-meshheading:16804904-Ovarian Neoplasms,
pubmed-meshheading:16804904-Prognosis,
pubmed-meshheading:16804904-Survival Rate,
pubmed-meshheading:16804904-beta Catenin
|
pubmed:year |
2006
|
pubmed:articleTitle |
Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression.
|
pubmed:affiliation |
Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|